TLR4 and colorectal cancer: Likewise, an anti-tumorigenic effect has also been suggested for the TLR4 agonist lipopolysaccharide (LPS; from Gram-negative bacteria) for the treatment of colorectal cancer and glioblastoma multiforme [5, 6].